Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition

Your next step starts here. Fill out the form and talk to us

Let's talk
Subscribe to Our Newsletter
logo Diatech Pharmacogenetics

Subscribe to Our Newsletter

You are leaving the U.S. & Canada Research Use Only (RUO) area.

The content you are about to access is intended for other markets and may include products or information not available in the U.S. or Canada.

Continue
Stay in U.S. & Canada RUO Area
logo Diatech Pharmacogenetics
Select Your Region

Please select your region to access the content that is most relevant to your location and applicable regulations.

EU / Rest of World
US / Canada